0.00Open0.30Pre Close0 Volume1 Open Interest70.00Strike Price0.00Turnover109.77%IV33.06%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.0747Delta0.0146Gamma176.12Leverage Ratio-0.0655Theta0.0010Rho13.15Eff Leverage0.0124Vega
G3636G : $iCAD Inc (ICAD.US)$ "With over 1,500 healthcare provider locations, facilitating over 8 million annual mammograms in 50 countries, iCAD's installed base and strong sales, engineering and marketing capabilities will provide us with immediate broad and valuable customer relationships and commercialization capabilities that can accelerate our existing DeepHealth objectives," said Dr. Howard Berger, President and CEO of RadNet. "This business combination is expected to accelerate our global leadership and commitment to AI-powered breast cancer screening, and positions us to further advance population health."
The deal will add iCAD's global network of over 1,500 healthcare locations to RadNet's DeepHealth platform, expanding access to advanced screening technologies. The companies believe the combination will speed up innovation, improve early cancer detection, and enhance patient outcomes worldwide